Rosetta Genomics to Host Business Update and 2014 Year End Financials Conference Call on March 17, 2015

PHILADELPHIA & REHOVOT, Israel--()--Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that following the close of the U.S. stock market on Monday, March 16, 2015, the Company will file its financial results for the year ended December 31, 2014 on Form 20-F with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F includes audited consolidated financial statements, as well as additional information regarding the Company. Once filed, the Form 20-F will be available at www.sec.gov and at www.rosettagenomics.com.

Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of Rosetta Genomics, will host a conference call on Tuesday, March 17, 2015 at 10:00 a.m. Eastern time to provide an update on the Company’s business and respond to questions.

Individuals interested in listening to the conference call may do so by dialing (866) 239-5859, or for international callers (702) 495-1913. The conference ID number is 4557508. The call is also being webcast, and can be accessed on the investor relations section of the Company’s Web site at www.rosettagenomics.com.

A telephone replay will be available through March 24, 2015 by dialing (855) 859-2056 or for international callers (404) 537-3406, and entering the Conference ID number 4557508. The webcast will be available on the Company’s website for 30 days following the completion of the call.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta’s cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, Rosetta’s development or commercialization of molecular diagnostics or therapeutics, the market acceptance of Rosetta’s cancer testing services, particularly the Rosetta Cancer Origin Test™ and the thyroid assay, Rosetta’s development of personalized medicine products and services, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2013 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

# # #

Contacts

Company Contact:
Rosetta Genomics
Ken Berlin, 609-419-9003
President & CEO
investors@rosettagenomics.com
or
Investor Contacts:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Contacts

Company Contact:
Rosetta Genomics
Ken Berlin, 609-419-9003
President & CEO
investors@rosettagenomics.com
or
Investor Contacts:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com